The BCR-ABL1 fusion gene has been observed in 95% of patients with chronic myeloid leukemia (CML), 20% to 35% of adult patients with acute lymphoblastic leukemia (ALL), and 2% to 5% of pediatric patients with ALL.[1] However, the incidence of Ph-positive acute myeloid leukemia (Ph + AML) is only 0.5% to 3%.[2] The median survival of patients with Ph + AML was 9 months.[3] Moreover, it has a low rate of complete remission (CR), a high risk of relapse, and an extremely poor prognosis. This evidence concerns the gene BCR and acute myeloid leukemia.